If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 71 - 80 of 292
Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Testing the addition of a type of drug called immunotherapy to the usual chemotherapy treatment for non-small cell lung cancer
Protocol No
ALLIANCE-ALCHEMIST-A081801
Categories
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Protocol No
ALLIANCE-ALCHEMIST-A151216
Categories
Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
Protocol No
ALLIANCE-N0577-CODEL
Categories
A Multi-site, Open-label, Phase II, Randomized, Controlled Trial to Compare the Efficacy of RO7198457 Versus Watchful Waiting in Resected, Stage II (High Risk) and Stage III Colorectal Cancer Patients Who Are ctDNA Positive Following Resection
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
Protocol No
BIONTECH-BNT-122-01
Categories
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Protocol No
ALLIANCE-A012103
Categories
A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO)
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
Protocol No
NRG-BR008-HERO
Categories
FLIP Device - Feasibility Study for Quantifying Fatty Liver Using Thermoacoustic Imaging
Assessment of Fatty Liver With Thermo-acoustic Device
Protocol No
GI-ENDRA-FLIP-DEVICE
Categories
Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC
S1803, Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Protocol No
SWOG-S1803-CTN-1706-DRAMMATIC
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination with Pembrolizumab in Subjects with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment with Standard of Care Therapy with an Immu
This trial is being run to find out how well the trial drug GEN1046 acts against NSCLC and if it is safe both as single treatment and in combination with Pembrolizumab to treat your NSCLC.
Protocol No
GENMAB-GCT1046-04
Categories
A Randomized, Open-Label Study of HLX10 plus Chemotherapy (Carboplatin-Etoposide) in Comparison with Atezolizumab Plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
A randomized study to compare Atezolizumab plus Chemotherapy vs HLX10 plus Chemo in ES-SCLC
Protocol No
SHB-HLX10-005-SCLC301-E
Categories